GlassScriptPhysician profile
Elizabeth Kujala
NPI 1215578414
$3,761.03
in general payments reported to CMS, 2019-2025
47 companies · $1,712 in 2025
The $1,712 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $463 · 2022: $888 · 2023: $152 · 2024: $546 · 2025: $1,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,192 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,192.49 |
| Education | $218.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $614.80 | 2021-2025 | |
| Celgene Corporation | $246.24 | 2021-2025 | Opdivo, Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $204.36 | 2021-2025 | Fruzaqla |
| Seagen INC. | $181.67 | 2021-2023 | Adcetris |
| Merck Sharp & Dohme LLC | $161.27 | 2022-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $146.51 | 2021-2025 | Lynparza |
| Janssen Biotech, INC. | $144.32 | 2024-2025 | Rybrevant, Carvykti, Tecvayli |
| Genentech USA, INC. | $142.04 | 2022 | |
| Sobi, INC | $139.49 | 2022-2024 | |
| Pfizer INC. | $132.36 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $119.00 | 2025 | |
| Eisai INC. | $119.00 | 2021-2025 | |
| Novocure INC. | $111.84 | 2025 | Optune Lua (Novottf-200t) |
| Genzyme Corporation | $86.97 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $75.68 | 2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Kujala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.